Ptc Therapeutics (PTCT) Gross Margin (2016 - 2026)

Ptc Therapeutics' Gross Margin history runs 11 years deep, the most recent figure standing at 89.72% for Q1 2026.

• In Q1 2026, Gross Margin fell 919.0% year-over-year to 89.72%; the TTM figure through Mar 2026 stood at 92.48% (down 402.0% YoY), while the FY2025 annual figure was 97.28%, up 440.0% from the prior year.
• Gross Margin was 89.72% for Q1 2026 at Ptc Therapeutics, down from 95.78% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 98.91% in Q1 2025 to a low of 89.72% in Q1 2026.
• Historically, Gross Margin has averaged 93.63% across 5 years, with a median of 93.56% in 2022.
• The sharpest annual moves came in 2025 and 2026: Gross Margin soared 592 bps in 2025, then slumped 919 bps in 2026.
• A 5-year view of Gross Margin shows it stood at 93.49% in 2022, then decreased by 3 bps to 90.52% in 2023, then grew by 2 bps to 92.36% in 2024, then increased by 4 bps to 95.78% in 2025, then slipped by 6 bps to 89.72% in 2026.
• The last three Gross Margin figures came in at 89.72% (Q1 2026), 95.78% (Q4 2025), and 92.52% (Q3 2025), per Business Quant data.